Clinical response to immune checkpoint inhibition in patients with advanced skin cancers receiving concurrent ruxolitinib therapy for hematologic malignancy.

Clinical response to immune checkpoint inhibition in patients with advanced skin cancers receiving concurrent ruxolitinib therapy for hematologic malignancy. Br J Dermatol. 2020 Oct 15;: Authors: Haddad N, Delyon J, Trabelsi Messai S, Herms F, Leccia MT, Lebbe C, Whitney J, Bhatia S, Basset-Seguin N Abstract Patients who are being treated with Janus-Kinase (JAK) inhibitors for hematologic conditions have a higher risk of developing non-melanoma skin cancers (NMSC) with an aggressive course1,2 . This has been attributed to relative immune-suppression that can accompany the use of JAK inhibitors, from their effects on T-cell signaling pathways3 . Acquired inactivating mutations in JAK 1 and JAK 2 genes have been reported to lead to a loss of programmed death ligand-1 (PD-L1) expression and a lack of response to interferon-γ (IFN-γ) in melanoma, contributing to acquired resistance to anti-programmed death 1 (PD-1) treatment4 . PMID: 33058221 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research